# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Study · id `cardio:ct-nct01218204` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01218204](<https://clinicaltrials.gov/study/NCT01218204>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01218204

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 287 participants.

## Technical summary

Registry record NCT01218204. Randomized; triple masking; primary purpose treatment. Start 2010-09-14 (actual); primary completion 2011-06-29 (actual). Results posted on 2017-11-08.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 287 participants (enrolled count; ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Started: 2010-09-14 (actual) (ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Primary completion: 2011-06-29 (actual) (ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Completion: 2011-06-29 (actual) (ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Results first posted: 2017-11-08 (ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01218204, source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01218204-2019-07-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
- Condition: Dyslipidaemias
- Condition: Dyslipidemias
- Intervention (Drug): 10mg atorvastatin
- Intervention (Drug): 80mg atorvastatin
- Intervention (Drug): GSK1292263 Placebo
- Intervention (Drug): 100mg GSK1292263
- Intervention (Drug): 300mg GSK1292263
- Intervention (Drug): 800mg GSK1292263
- Intervention (Drug): 10mg ezetimibe
- Intervention (Other): Washout
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: f12ff4df593fdde97dad8dfe8b0f86f6e21da2b804287cf47100fc908d993158
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
